Immunotherapy plus radiation before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the immunotherapy drug sintilimab along with low-dose radiation before surgery can help shrink stomach cancer that has a specific DNA repair defect (dMMR/MSI-H). The goal is to make surgery more effective and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 80 years old.
- Have a type of stomach cancer that is locally advanced (can be surgically removed) and has a specific DNA repair defect (called dMMR or MSI-H).
- Not have had any prior cancer treatment for this disease, including chemotherapy, radiation, or immunotherapy.
- Be in good enough physical condition (ECOG score 0 or 1) to receive the study treatments.
- Be willing to provide blood, stool, and tissue samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.